高级搜索
乳腺良恶性病变组织中PRL和三种酶的分布及在乳癌中相互关系[J]. 肿瘤防治研究, 1994, 21(1): 8-10.
引用本文: 乳腺良恶性病变组织中PRL和三种酶的分布及在乳癌中相互关系[J]. 肿瘤防治研究, 1994, 21(1): 8-10.
DISTRIBUTIONS OF PRL,NADHDH, GDH AND LDH ACTIVITY IN BREAST LESIONS AND THEIR RELATIONSRIPS IN BREAST CANCER[J]. Cancer Research on Prevention and Treatment, 1994, 21(1): 8-10.
Citation: DISTRIBUTIONS OF PRL,NADHDH, GDH AND LDH ACTIVITY IN BREAST LESIONS AND THEIR RELATIONSRIPS IN BREAST CANCER[J]. Cancer Research on Prevention and Treatment, 1994, 21(1): 8-10.

乳腺良恶性病变组织中PRL和三种酶的分布及在乳癌中相互关系

DISTRIBUTIONS OF PRL,NADHDH, GDH AND LDH ACTIVITY IN BREAST LESIONS AND THEIR RELATIONSRIPS IN BREAST CANCER

  • 摘要: 本文应用组化方法研究乳腺良恶性病变组织中PRL和NADHDH、GDH、LDH三种酶活性分布及在乳癌中相互关系.乳癌和良性病变PRL阳性率分别为80.5%和85.7%;乳癌组织NADHDH、GDH和LDH高酶活性率分别为73.2%、39%和82.9%,良性病变分别为51.4%、51.4%和65.7%,NADHDH和LDH高酶活性率乳癌高于良性病变(P<0.05);PRL阳性率及半定量分级均与NADHDH和LDH高酶活性率有高度密切关系,GDH和LDH高酶率均与NADHDH高酶活性率存在密切关系.上述结果提示:大部分乳癌存在PRL依赖性,PRL可能参与乳癌形成;NADHDH、GDH和LDH可能是较好的乳癌酶生物学标记物,检测这些酶活性可能对估测乳癌预后及临床治疗方案选择有较重要意义;乳癌组织中PRL可能诱导NADHDH和LDH酶活性.

     

    Abstract: The distributions of PRL (prolactin),NADHDH (NADH dehydrogerose), GDH (glutamicdehydrogenase) and LDH (Lactate dehydrogenase) activity in breast lesions and their relationshipsin breast cancer were studied by histochemical methods. The PRL positive rate in breast cancer andbenign lesions was 80.5% and 85.7% respectively; the highly enzyme activity rate of NADHDH,GDH and LDH in breast cancer was 73. 2%, 39% and 82. 9% respectively, and in benign lesionswas 51.4%,51. 4% and 65. 7% respectively, the activity of NADHDH and LDH had siguifical increasing in breast cancer. Close correlations were found among the PRL POsitive rate or semiquanative grades and the NADHDH, LDH activity, and close correlations also were found among theGDH, LDH activity and the NADHDH activity. These results suggested: A large of breast cancersmight be dependence of PRL;The NADHDH, GDH and LDH activity might be good enzyme biological marker of breast cancer and might have important significances in predicting prognostic value and choosing scheme of therapy of breast cancer.

     

/

返回文章
返回